Madrigal Pharmaceuticals, Inc. (MDGL)
NASDAQ: MDGL · Real-Time Price · USD
300.75
+1.24 (0.41%)
At close: Jun 27, 2025, 4:00 PM
296.00
-4.75 (-1.58%)
After-hours: Jun 27, 2025, 5:57 PM EDT
Madrigal Pharmaceuticals Stock Forecast
Stock Price Forecast
The 9 analysts that cover Madrigal Pharmaceuticals stock have a consensus rating of "Strong Buy" and an average price target of $420.63, which forecasts a 39.86% increase in the stock price over the next year. The lowest target is $350 and the highest is $469.
Price Target: $420.63 (+39.86%)
Analyst Consensus: Strong Buy
* Price targets were last updated on May 2, 2025.
Analyst Ratings
The average analyst rating for Madrigal Pharmaceuticals stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Jan '25 | Feb '25 | Mar '25 | Apr '25 | May '25 | Jun '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 5 | 5 | 5 | 3 | 5 | 5 |
| Buy | 6 | 6 | 6 | 4 | 4 | 3 |
| Hold | 2 | 2 | 2 | 2 | 1 | 1 |
| Sell | 1 | 1 | 1 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 14 | 14 | 14 | 9 | 10 | 9 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| UBS | UBS | Strong Buy Maintains $441 → $458 | Strong Buy | Maintains | $441 → $458 | +52.29% | May 2, 2025 |
| B. Riley Securities | B. Riley Securities | Strong Buy Reiterates $422 → $460 | Strong Buy | Reiterates | $422 → $460 | +52.95% | May 2, 2025 |
| Canaccord Genuity | Canaccord Genuity | Strong Buy Maintains $394 → $420 | Strong Buy | Maintains | $394 → $420 | +39.65% | May 2, 2025 |
| JMP Securities | JMP Securities | Buy Reiterates $443 | Buy | Reiterates | $443 | +47.30% | Apr 24, 2025 |
| Citigroup | Citigroup | Strong Buy Maintains $378 → $469 | Strong Buy | Maintains | $378 → $469 | +55.94% | Feb 27, 2025 |
Financial Forecast
Revenue This Year
695.62M
from 180.13M
Increased by 286.17%
Revenue Next Year
1.14B
from 695.62M
Increased by 64.17%
EPS This Year
-13.54
from -21.90
EPS Next Year
0.65
from -13.54
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 827.8M | 1.4B | 2.2B | ||
| Avg | 695.6M | 1.1B | 1.8B | ||
| Low | 587.4M | 862.7M | 1.2B |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 359.5% | 104.6% | 92.6% | ||
| Avg | 286.2% | 64.2% | 58.9% | ||
| Low | 226.1% | 24.0% | 1.4% |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | -7.18 | 20.31 | 36.67 | ||
| Avg | -13.54 | 0.65 | 18.79 | ||
| Low | -19.54 | -12.23 | -1.95 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | - | - | 5,562.8% | ||
| Avg | - | - | 2,801.2% | ||
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.